Glenmark to progress BeiGene’s key assets in India, a market where rival PD-1 inhibitors and BTK inhibitors have a head start. All eyes are on the regulatory pathway, which provides for a waiver of local trial requirements for new drugs on a case-by-case basis, subject to certain criteria.

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.

US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.

BeiGene co-founder and chair of the major global biotech's Scientific Advisory Board, Dr. Xiaodong Wang, sits down with Scrip in an exclusive audio interview to shed light on the rapid rise of China's biotech innovation, the country's role in BeiGene's global strategy and the next big things to watch.